Trial Outcomes & Findings for Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa (NCT NCT02513485)

NCT ID: NCT02513485

Last Updated: 2022-09-19

Results Overview

Corticostriatal connectivity was assessed by functional magnetic resonance imaging (fMRI). Resting-state and task-based (monetary incentive delay \[MID\]) fMRI scans were conducted on a 3 Tesla Siemens Trio MRI scanner. Subject-level correlations for degree of cortical and striatal functional connectivity were Fisher's Z transformed {Z(R)=0.5ln\[(1+R)/(1-R)\]}, a standard method for calculating fMRI functional connectivity. Greater Fisher's Z-scores reflected stronger correlated fMRI activity (i.e., higher corticostriatal connectivity).

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

57 participants

Primary outcome timeframe

Scans approximately 45 min post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)

Results posted on

2022-09-19

Participant Flow

Participants were enrolled between October 2015 and February 2020.

Participant milestones

Participant milestones
Measure
Sinemet/Placebo
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
Subjects with major depression were given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo was given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Overall Study
STARTED
28
29
Overall Study
COMPLETED
27
29
Overall Study
NOT COMPLETED
1
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Sinemet/Placebo
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
Subjects with major depression were given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo was given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Overall Study
Adverse Event
1
0

Baseline Characteristics

Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Sinemet/Placebo
n=27 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=29 Participants
Subjects with major depression were given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo was given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Total
n=56 Participants
Total of all reporting groups
Age, Continuous
36.1 years
STANDARD_DEVIATION 11.5 • n=99 Participants
38.7 years
STANDARD_DEVIATION 10.3 • n=107 Participants
37.5 years
STANDARD_DEVIATION 10.9 • n=206 Participants
Sex: Female, Male
Female
20 Participants
n=99 Participants
21 Participants
n=107 Participants
41 Participants
n=206 Participants
Sex: Female, Male
Male
7 Participants
n=99 Participants
8 Participants
n=107 Participants
15 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=99 Participants
5 Participants
n=107 Participants
6 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
26 Participants
n=99 Participants
24 Participants
n=107 Participants
50 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
15 Participants
n=99 Participants
8 Participants
n=107 Participants
23 Participants
n=206 Participants
Race (NIH/OMB)
White
11 Participants
n=99 Participants
20 Participants
n=107 Participants
31 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
27 participants
n=99 Participants
29 participants
n=107 Participants
56 participants
n=206 Participants

PRIMARY outcome

Timeframe: Scans approximately 45 min post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)

Population: The number analyzed in one or more rows correspond to the number with available and analyzable resting fMRI scans both pre and post drug and placebo.

Corticostriatal connectivity was assessed by functional magnetic resonance imaging (fMRI). Resting-state and task-based (monetary incentive delay \[MID\]) fMRI scans were conducted on a 3 Tesla Siemens Trio MRI scanner. Subject-level correlations for degree of cortical and striatal functional connectivity were Fisher's Z transformed {Z(R)=0.5ln\[(1+R)/(1-R)\]}, a standard method for calculating fMRI functional connectivity. Greater Fisher's Z-scores reflected stronger correlated fMRI activity (i.e., higher corticostriatal connectivity).

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=21 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=19 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Change in Functional Corticostriatal Connectivity
Visit 1 resting corticostriatal connectivity response to drug/placebo (post minus pre)
0.10 Z-score
Standard Deviation 0.22
0.04 Z-score
Standard Deviation 0.17
Change in Functional Corticostriatal Connectivity
Visit 2 resting corticostriatal connectivity response to drug/placebo (post minus pre)
0.07 Z-score
Standard Deviation 0.18
0.00 Z-score
Standard Deviation 0.23
Change in Functional Corticostriatal Connectivity
Visit 1 resting corticostriatal connectivity post drug/placebo
0.22 Z-score
Standard Deviation 0.15
0.24 Z-score
Standard Deviation 0.12
Change in Functional Corticostriatal Connectivity
Visit 2 resting corticostriatal connectivity post drug/placebo
0.24 Z-score
Standard Deviation 0.18
0.17 Z-score
Standard Deviation 0.18
Change in Functional Corticostriatal Connectivity
Visit 1 task (reward anticipation) corticostriatal connectivity post drug/placebo
0.02 Z-score
Standard Deviation 0.16
0.00 Z-score
Standard Deviation 0.15
Change in Functional Corticostriatal Connectivity
Visit 2 task (reward anticipation) corticostriatal connectivity post drug/placebo
-0.04 Z-score
Standard Deviation 0.19
-0.03 Z-score
Standard Deviation 0.16

PRIMARY outcome

Timeframe: Scans approximately 45 minutes post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)

Population: The number analyzed in each row correspond to the number available and analyzable with resting fMRI scans both pre and post drug and placebo.

Peripheral blood samples were analyzed for levels of immune markers like plasma C-reactive protein (CRP), interleukin-6 (IL-6), soluble interleukin-6 receptor (sIL-6R), tumor necrosis factor (TNF) -alpha, soluble cytokine receptor2 (TNFR 2), interleukin-1 beta (IL-1 beta), interleukin-1 receptor antagonist (IL-1Ra), interleukin 10 (IL-10) and monocyte chemoattractant protein-1 (MCP-1).

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=21 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=19 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP mg/L and Visit 1 resting connectivity response to drug/placebo (post minus pre)
0.36 Pearson's r Correlation Coefficient
Interval -0.16 to 0.73
-0.15 Pearson's r Correlation Coefficient
Interval -0.61 to 0.4
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP mg/L and Visit 2 resting connectivity response to drug/placebo (post minus pre)
-0.12 Pearson's r Correlation Coefficient
Interval -0.58 to 0.4
0.44 Pearson's r Correlation Coefficient
Interval -0.09 to 0.78
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP mg/L and Visit 1 resting connectivity post drug/placebo
0.10 Pearson's r Correlation Coefficient
Interval -0.35 to 0.51
0.15 Pearson's r Correlation Coefficient
Interval -0.33 to 0.56
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP mg/L and Visit 2 resting connectivity post drug/placebo
-0.10 Pearson's r Correlation Coefficient
Interval -0.51 to 0.35
0.41 Pearson's r Correlation Coefficient
Interval -0.06 to 0.73
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP mg/L and Visit 1 task (reward anticipation) connectivity post drug/placebo
0.49 Pearson's r Correlation Coefficient
Interval -0.01 to 0.79
-0.31 Pearson's r Correlation Coefficient
Interval -0.71 to 0.25
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP mg/L and Visit 2 task (reward anticipation) connectivity post drug/placebo
0.10 Pearson's r Correlation Coefficient
Interval -0.42 to 0.57
0.25 Pearson's r Correlation Coefficient
Interval -0.3 to 0.68
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP > vs. < 2 mg/ and Visit 1 resting connectivity response to drug/placebo (post minus pre)
0.20 Pearson's r Correlation Coefficient
Interval -0.32 to 0.64
0.04 Pearson's r Correlation Coefficient
Interval -0.48 to 0.54
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP > vs. < 2 mg/L and Visit 2 resting connectivity response to drug/placebo (post minus pre)
-0.33 Pearson's r Correlation Coefficient
Interval -0.71 to 0.2
0.52 Pearson's r Correlation Coefficient
Interval 0.01 to 0.81
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP > vs. < 2 mg/L and Visit 1 resting connectivity post drug/placebo
0.12 Pearson's r Correlation Coefficient
Interval -0.33 to 0.53
0.17 Pearson's r Correlation Coefficient
Interval -0.31 to 0.58
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP > vs. < 2 mg/L and Visit 2 resting connectivity post drug/placebo
-0.31 Pearson's r Correlation Coefficient
Interval -0.66 to 0.14
0.38 Pearson's r Correlation Coefficient
Interval -0.09 to 0.71
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP > vs. < 2 mg/L and Visit 1 task (reward anticipation) connectivity post drug/placebo
0.22 Pearson's r Correlation Coefficient
Interval -0.31 to 0.65
-0.35 Pearson's r Correlation Coefficient
Interval -0.73 to 0.2
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
CRP > vs. < 2 mg/L and Visit 2 task (reward anticipation) connectivity post drug/placebo
-0.18 Pearson's r Correlation Coefficient
Interval -0.62 to 0.35
0.48 Pearson's r Correlation Coefficient
Interval -0.05 to 0.8
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
Sum of cytokine Z scores and Visit 1 resting connectivity response to drug/placebo (post minus pre)
0.40 Pearson's r Correlation Coefficient
Interval -0.12 to 0.75
-0.05 Pearson's r Correlation Coefficient
Interval -0.56 to 0.49
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
Sum of cytokine Z scores and Visit 2 resting connectivity response to drug/placebo (post minus pre)
-0.14 Pearson's r Correlation Coefficient
Interval -0.58 to 0.39
0.29 Pearson's r Correlation Coefficient
Interval -0.29 to 0.71
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
Sum of cytokine Z scores and Visit 1 resting connectivity post drug/placebo
0.15 Pearson's r Correlation Coefficient
Interval -0.3 to 0.55
-0.05 Pearson's r Correlation Coefficient
Interval -0.57 to 0.49
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
Sum of cytokine Z scores and Visit 2 resting connectivity post drug/placebo
-0.22 Pearson's r Correlation Coefficient
Interval -0.6 to 0.23
0.08 Pearson's r Correlation Coefficient
Interval -0.4 to 0.53
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
Sum of cytokine Z scores and Visit 1 task (reward anticipation) connectivity post drug/placebo
0.26 Pearson's r Correlation Coefficient
Interval -0.27 to 0.67
-0.34 Pearson's r Correlation Coefficient
Interval -0.74 to 0.23
Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
Sum of cytokine Z scores and Visit 2 task (reward anticipation) connectivity post drug/placebo
0.04 Pearson's r Correlation Coefficient
Interval -0.45 to 0.53
-0.18 Pearson's r Correlation Coefficient
Interval -0.65 to 0.39

SECONDARY outcome

Timeframe: At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)

Population: This analysis includes participants who completed this assessment and had usable data. Two participants in each study arm did not complete this assessment at any time point. Two participants in the Placebo/Sinemet group had unusable data for the baseline assessment.

The Effort-Expenditure for Rewards Task (EEfRT) is a computer-based multi-trial task used to objectively assess motivation. Possible results range between 0 to1 with 1 being a better outcome. Results show mean probability of hard (high effort) choice.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=25 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=27 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Effort-Expenditure for Rewards Task (EEfRT) Neurocognitive Test
Visit 2: 2-3 hrs post drug/placebo
0.30 Probability of hard/high effort choices
Standard Deviation 0.15
0.34 Probability of hard/high effort choices
Standard Deviation 0.21
Effort-Expenditure for Rewards Task (EEfRT) Neurocognitive Test
Baseline Visit (Task Practice)
0.29 Probability of hard/high effort choices
Standard Deviation 0.13
0.39 Probability of hard/high effort choices
Standard Deviation 0.17
Effort-Expenditure for Rewards Task (EEfRT) Neurocognitive Test
Visit 1: 2-3 hrs post drug/placebo
0.28 Probability of hard/high effort choices
Standard Deviation 0.13
0.34 Probability of hard/high effort choices
Standard Deviation 0.17

SECONDARY outcome

Timeframe: At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)

Population: This analysis includes participants who completed this assessment and had usable data. One participant in the Sinemet/Placebo arm and two participants in the Placebo/Sinemet arm did not complete this assessment at any time point. Three participants in the Placebo/Sinemet group had unusable data for the baseline assessment.

The Trail Making Test (TMT) is used to measure basic attention and psychomotor processing speed. Time taken to complete each task is recorded in seconds, whereby the greater the number of seconds, the slower the psychomotor speed.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=26 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=27 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
The Trail Making Test (TMT) Neurocognitive Assessment
Baseline Visit (Task Practice)
24.0 seconds
Standard Deviation 10.0
23.7 seconds
Standard Deviation 4.7
The Trail Making Test (TMT) Neurocognitive Assessment
Visit 1: 2-3 hrs post drug/placebo
21.7 seconds
Standard Deviation 8.8
21.0 seconds
Standard Deviation 5.2
The Trail Making Test (TMT) Neurocognitive Assessment
Visit 2: 2-3 hrs post drug/placebo
23.0 seconds
Standard Deviation 13.8
19.7 seconds
Standard Deviation 4.6

SECONDARY outcome

Timeframe: At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)

Population: This analysis includes participants who completed this assessment and had usable data. One participant in the Placebo/Sinemet arm did not complete this assessment at any time point and one had unusable data for the baseline assessment.

The Digit Symbol Task was used to assess graphomotor speed, visual scanning and memory processing speed involving numbers and a corresponding blank box where subjects are asked to fill in matching symbol as fast as they can. Results show the average number of correct symbols completed in up to 100 boxes in 90 seconds.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=27 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=28 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Digit Symbol Task Neurocognitive Test
Baseline Visit (Task Practice)
52.0 number of correct symbols
Standard Deviation 8.8
54.9 number of correct symbols
Standard Deviation 11.3
Digit Symbol Task Neurocognitive Test
Visit 1: 2-3 hrs post drug/placebo
61.3 number of correct symbols
Standard Deviation 11.3
64.5 number of correct symbols
Standard Deviation 10.2
Digit Symbol Task Neurocognitive Test
Visit 2: 2-3 hrs post drug/placebo
66.6 number of correct symbols
Standard Deviation 11.7
66.4 number of correct symbols
Standard Deviation 11.6

SECONDARY outcome

Timeframe: At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)

Population: This analysis includes participants who completed this assessment and had usable data. One participant in the Placebo/Sinemet arm did not complete this assessment at any time point and one had unusable data for the baseline assessment.

The Finger Tapping Task (FTT) assesses motor speed and can detect subtle motor impairment. The test measures the average number of taps per 10 second trial. A greater number of taps reflects faster motor speed.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=27 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=28 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Finger Tapping Task (FTT) Neurocognitive Test
Baseline Visit (Task Practice)
52.0 number of taps
Standard Deviation 8.8
54.9 number of taps
Standard Deviation 11.3
Finger Tapping Task (FTT) Neurocognitive Test
Visit 1: 2-3 hrs post drug/placebo
61.3 number of taps
Standard Deviation 11.3
64.5 number of taps
Standard Deviation 10.2
Finger Tapping Task (FTT) Neurocognitive Test
Visit 2: 2-3 hrs post drug/placebo
66.6 number of taps
Standard Deviation 11.7
66.4 number of taps
Standard Deviation 11.6

SECONDARY outcome

Timeframe: At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)

Population: This analysis includes participants who completed this assessment and had usable data. Seven participants in the Sinemet/Placebo arm and 8 participants in the Placebo/Sinemet arm did not complete this assessment at any time point. One participant in each study arm had unusable data for the baseline assessment.

The reaction time test includes simple and choice reaction time tasks and is divided into 5 stages requiring increasingly complex chains of responses. The task provided distinction between reaction (or decision) time and movement latencies (milliseconds) based on touch responses made to a single (simple) or chosen from multiple (choice) stimuli flashed on a computer screen. Results show mean response latency in milliseconds.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=20 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=21 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Reaction Time Task (CANTAB) Neurocognitive Test
Baseline Simple Motor Time
266.92 milliseconds
Standard Deviation 59.55
276.12 milliseconds
Standard Deviation 94.35
Reaction Time Task (CANTAB) Neurocognitive Test
Baseline Choice Motor Time
286.82 milliseconds
Standard Deviation 50.47
299.57 milliseconds
Standard Deviation 89.33
Reaction Time Task (CANTAB) Neurocognitive Test
Baseline Simple Reaction Time
360.84 milliseconds
Standard Deviation 38.38
356.53 milliseconds
Standard Deviation 42.11
Reaction Time Task (CANTAB) Neurocognitive Test
Baseline Choice Reaction Time
397.60 milliseconds
Standard Deviation 46.74
394.82 milliseconds
Standard Deviation 31.31
Reaction Time Task (CANTAB) Neurocognitive Test
Visit 1: 2-3 hrs post drug/placebo Simple Motor Time
240.62 milliseconds
Standard Deviation 55.50
258.53 milliseconds
Standard Deviation 89.29
Reaction Time Task (CANTAB) Neurocognitive Test
Visit 1: 2-3 hrs post drug/placebo Choice Motor Time
268.69 milliseconds
Standard Deviation 52.17
284.94 milliseconds
Standard Deviation 75.16
Reaction Time Task (CANTAB) Neurocognitive Test
Visit 1: 2-3 hrs post drug/placebo Simple Reaction Time
256.99 milliseconds
Standard Deviation 35.69
348.93 milliseconds
Standard Deviation 26.14
Reaction Time Task (CANTAB) Neurocognitive Test
Visit 1: 2-3 hrs post drug/placebo Choice Reaction Time
397.07 milliseconds
Standard Deviation 39.50
385.03 milliseconds
Standard Deviation 22.59
Reaction Time Task (CANTAB) Neurocognitive Test
Visit 2: 2-3 hrs post drug/placebo Simple Motor Time
241.28 milliseconds
Standard Deviation 46.34
268.37 milliseconds
Standard Deviation 93.51
Reaction Time Task (CANTAB) Neurocognitive Test
Visit 2: 2-3 hrs post drug/placebo Choice Motor Time
260.47 milliseconds
Standard Deviation 42.43
296.94 milliseconds
Standard Deviation 83.62
Reaction Time Task (CANTAB) Neurocognitive Test
Visit 2: 2-3 hrs post drug/placebo Simple Reaction Time
358.59 milliseconds
Standard Deviation 35.87
361.76 milliseconds
Standard Deviation 47.55
Reaction Time Task (CANTAB) Neurocognitive Test
Visit 2: 2-3 hrs post drug/placebo Choice Reaction Time
395.22 milliseconds
Standard Deviation 33.75
396.68 milliseconds
Standard Deviation 38.93

SECONDARY outcome

Timeframe: At baseline and Visit 1, Visit 2 (spaced by approximately 1 week)

The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure severity of fatigue based on five dimensions of fatigue, general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. The total MFI scores range from 20 to 100 where high scores indicate greater fatigue.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=27 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=29 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Multidimensional Fatigue Inventory (MFI) Self-report Questionnaire
Baseline
74.7 score on a scale
Standard Deviation 10.9
72.7 score on a scale
Standard Deviation 13.5
Multidimensional Fatigue Inventory (MFI) Self-report Questionnaire
Visit 1: Pre drug/placebo
76.7 score on a scale
Standard Deviation 10.7
74.2 score on a scale
Standard Deviation 15.05
Multidimensional Fatigue Inventory (MFI) Self-report Questionnaire
Visit 2: Pre drug/placebo
75.7 score on a scale
Standard Deviation 10.5
74.1 score on a scale
Standard Deviation 14.9

SECONDARY outcome

Timeframe: Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo

Population: This analysis includes participants who completed this assessment.

The Snaith-Hamilton Pleasure Scale (SHAPS), a 14-item self-report scale with high psychometric validity for assessing the presence of anhedonia, was used to assess hedonic capacity. Participants rated how much they agreed or disagreed with the 14 items phrased as "I would enjoy \_\_" based on their ability to experience pleasure. Of the four possible response categories (Definitely Agree, Agree, Disagree, and Strongly Disagree), either of the Disagree responses received a score of 1 and either of the Agree responses received a score of 0. The SHAPS score calculated as the sum of these 14 items ranged from 0 to 14, and higher SHAPS scores indicated greater anhedonia.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=27 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=28 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Snaith-Hamilton Pleasure Scale (SHAPS) Self-report Questionnaire
Visit 1: Pre drug/placebo
4.7 score on a scale
Standard Deviation 3.5
5.8 score on a scale
Standard Deviation 3.7
Snaith-Hamilton Pleasure Scale (SHAPS) Self-report Questionnaire
Visit 1: 1-2 hrs post drug/placebo
4.3 score on a scale
Standard Deviation 4.0
4.6 score on a scale
Standard Deviation 3.7
Snaith-Hamilton Pleasure Scale (SHAPS) Self-report Questionnaire
Visit 2: Pre drug/placebo
4.2 score on a scale
Standard Deviation 3.9
4.9 score on a scale
Standard Deviation 4.2
Snaith-Hamilton Pleasure Scale (SHAPS) Self-report Questionnaire
Visit 2: 1-2 hrs post drug/placebo
4.2 score on a scale
Standard Deviation 4.4
3.9 score on a scale
Standard Deviation 4.2

SECONDARY outcome

Timeframe: At baseline and Visit 1: Pre drug/placebo, Visit 2: Pre drug/placebo (spaced by approximately 1 week)

Population: Three participants in the Sinemet/Placebo arm and four participants in the Placebo/Sinemet arm had unusable data for the baseline assessment.

The Inventory of Depressive Symptoms-Self Report (IDS-SR) is a 30-item self-report instrument with excellent psychometric properties for measuring symptom constructs consistent with current Diagnostic and Statistical Manual of Mental Disorders (DSM) nosology and that is widely used to measure depression severity in clinical trials. Response scores are summed and range from 0 to 84, with higher scores reflecting greater depression severity.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=27 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=29 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Inventory of Depressive Symptoms-Self Report (IDS-SR) Questionnaire
Baseline
37.9 score on a scale
Standard Deviation 65
35.0 score on a scale
Standard Deviation 10.8
Inventory of Depressive Symptoms-Self Report (IDS-SR) Questionnaire
Visit 1: Pre drug/placebo
37.6 score on a scale
Standard Deviation 6.3
31.8 score on a scale
Standard Deviation 10.7
Inventory of Depressive Symptoms-Self Report (IDS-SR) Questionnaire
Visit 2: Pre drug/placebo
34.7 score on a scale
Standard Deviation 8.6
32.0 score on a scale
Standard Deviation 11.1

SECONDARY outcome

Timeframe: Visit 1: Pre drug/placebo, Visit 2: Pre drug/placebo (spaced by approximately 1 week)

The Beck Depression Inventory-II (BDI-II) is a widely used self-report for measuring depression severity over the past two weeks and the anhedonia subscale is one of several validated subscales in the BDI-II. Responses are given on a 4-point scale where 0 = the symptom of depression has not been experienced and 3 = the symptom of depression is severe. The anhedonia subscale score is created by summing responses to four items of the BDI-II that assess loss of pleasure, loss of interest, loss of energy, loss of sex drive. The total score of the anhedonia subscale ranges from 0 to 12 where higher scores reflect greater severity of anhedonia symptoms.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=27 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=29 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Beck Depression Inventory (BDI-II), Anhedonia Subscale Score
Visit 1: Pre drug/placebo
6.4 score on a scale
Standard Deviation 2.4
5.9 score on a scale
Standard Deviation 2.5
Beck Depression Inventory (BDI-II), Anhedonia Subscale Score
Visit 2: Pre drug/placebo
5.7 score on a scale
Standard Deviation 2.9
5.9 score on a scale
Standard Deviation 2.8

SECONDARY outcome

Timeframe: Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo

Population: This analysis includes participants who completed this assessment.

The Profile of Mood States (POMS) scale is a 30-item psychological rating scale used to assess transient, distinct mood states. Participants rate the extent to which they feel unhappy, blue, lonely, gloomy, and worthless on a scale from 0 (not at all) to 4 (extremely). Scores range from 0 to 120 with higher scores reflecting a more negative mood state.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=25 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=26 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Profile of Mood States (POMS) Scale
Visit 1: Pre drug/placebo
60.2 score on a scale
Standard Deviation 17.6
57.0 score on a scale
Standard Deviation 14.6
Profile of Mood States (POMS) Scale
Visit 1: 1-2 hrs post drug/placebo
54.0 score on a scale
Standard Deviation 15.1
51.5 score on a scale
Standard Deviation 11.8
Profile of Mood States (POMS) Scale
Visit 2: Pre drug/placebo
53.0 score on a scale
Standard Deviation 12.7
56.2 score on a scale
Standard Deviation 14.3
Profile of Mood States (POMS) Scale
Visit 2: 1-2 hrs post drug/placebo
48.5 score on a scale
Standard Deviation 14.3
51.0 score on a scale
Standard Deviation 11.5

SECONDARY outcome

Timeframe: Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo

Population: This analysis includes participants who completed this assessment.

The 20-item self-report State-Trait Anxiety Inventory (STAI) State scale was used to measure severity of anxiety symptoms. Total scores range from 20 to 80 with higher scores reflecting greater anxiety. Scores in the high 40s are considered clinically significant.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=14 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=16 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
State-Trait Anxiety Inventory (STAI) State Scale
Visit 1: Pre drug/placebo
52.1 score on a scale
Standard Deviation 12.3
46.5 score on a scale
Standard Deviation 10.6
State-Trait Anxiety Inventory (STAI) State Scale
Visit 1: 1-2 hrs post drug/placebo
49.2 score on a scale
Standard Deviation 9.3
42.2 score on a scale
Standard Deviation 9.3
State-Trait Anxiety Inventory (STAI) State Scale
Visit 2: Pre drug/placebo
51.3 score on a scale
Standard Deviation 9.9
45.9 score on a scale
Standard Deviation 14.0
State-Trait Anxiety Inventory (STAI) State Scale
Visit 2: 1-2 hrs post drug/placebo
43.4 score on a scale
Standard Deviation 12.0
43.0 score on a scale
Standard Deviation 9.9

SECONDARY outcome

Timeframe: Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo

Population: This analysis includes participants who completed this assessment.

The motivation and pleasure (MAP) questionnaire is an 18-item self-report inventory that was created to disentangle state-wise motivational and consummatory components of everyday activities over a 24-hour period. This scale was used to assess self-reported changes in symptoms of anhedonia before and after inflammation blockade. Respondents respond to statements about daily activities on a scale from 0 (no pleasure/not at all) to 4 (extreme pleasure/very often). Total scores range from 0 to 72 where higher scores indicate greater motivation and effort given to everyday situations.

Outcome measures

Outcome measures
Measure
Sinemet/Placebo
n=10 Participants
Subjects with major depression were given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet was given first followed by placebo at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally at Visit 1 or Visit 2.
Placebo/Sinemet
n=7 Participants
Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit. Levodopa+carbidopa: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2. Placebo: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Change in Motivation and Pleasure (MAP) Scale Score
Visit 1: Pre drug/placebo
25.5 score on a scale
Standard Deviation 11.5
26.6 score on a scale
Standard Deviation 13.8
Change in Motivation and Pleasure (MAP) Scale Score
Visit 1: 1-2 hrs post drug/placebo
26.9 score on a scale
Standard Deviation 11.1
25.4 score on a scale
Standard Deviation 16.1
Change in Motivation and Pleasure (MAP) Scale Score
Visit 2: Pre drug/placebo
28.9 score on a scale
Standard Deviation 13.6
25.1 score on a scale
Standard Deviation 22.0
Change in Motivation and Pleasure (MAP) Scale Score
Visit 2: 1-2 hrs post drug/placebo
29.2 score on a scale
Standard Deviation 13.7
25.1 score on a scale
Standard Deviation 21.3

OTHER_PRE_SPECIFIED outcome

Timeframe: Scans approximately 45 minutes post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)

The cerebral blood flow (CBF) before and after Sinemet (250 mg levodopa/ 50mg carbidopa) or placebo administration was assessed by arterial spin labeling (ASL) fMRI.

Outcome measures

Outcome data not reported

Adverse Events

Sinemet

Serious events: 0 serious events
Other events: 50 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 11 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Sinemet
n=57 participants at risk
Levodopa+carbidopa (Sinemet) is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet was administered orally either at Visit 1 if the subject was in the Sinemet/Placebo group or, at Visit 2 if the subject was in the Placebo/Sinemet group.
Placebo
n=56 participants at risk
Placebo: A placebo is a sugar pill that has no therapeutic effect and was administered orally either at Visit 1 if the subject was in the Placebo/Sinemet group or, at Visit 2 if the subject was in the Sinemet/Placebo group.
Nervous system disorders
Headache
10.5%
6/57 • Number of events 6 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.
8.9%
5/56 • Number of events 5 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.
Gastrointestinal disorders
Vomiting
14.0%
8/57 • Number of events 9 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.
1.8%
1/56 • Number of events 1 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.
Nervous system disorders
Dizziness
10.5%
6/57 • Number of events 6 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.
3.6%
2/56 • Number of events 2 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.
Gastrointestinal disorders
Nausea
38.6%
22/57 • Number of events 27 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.
5.4%
3/56 • Number of events 3 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.
General disorders
Lightheadedness
8.8%
5/57 • Number of events 5 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.
0.00%
0/56 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.
General disorders
Feeling Hot
5.3%
3/57 • Number of events 3 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.
0.00%
0/56 • From time of consent until follow up (up to 2 weeks).
The population analyzed includes all subjects who were randomized and had taken at least one dose of the medication.

Additional Information

Dr. Jennifer Felger

Emory University

Phone: 404-727-3987

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place